3D Cell Culture Technologies In Drug Development
Learn about human, disease-specific tissue microenvironments for testing drug efficacy and safety from leading provider, zPREDICTA.
Conventional cell culture models lack tissue microenvironment, and thus, have limited physiological relevance. Emerging 3D culture systems, such as zPREDICTA’s disease models, mimic the native architecture of human tissues in an organ- and disease-specific manner, demonstrating high correlation with clinical response.
Join this 45-minute session to learn about:
- Importance of incorporating organ-specific human tissue microenvironment for testing drug efficacy and safety.
- Versatile design of 3D culture models for anticancer drug screening, target discovery, and immuno-oncology.
- Clinical study data demonstrating high correlation of zPREDICTA models with clinical response.
January 31, 2019 | 9am PST/12pm EST/5pm UTC
Who should attend:
- Researchers developing new anticancer drugs
- Scientists performing screening of anticancer agents
- Laboratories designing immuno-oncology therapies
About Our Speaker, Julia Kirshner:
Julia Kirshner, Ph.D., is the CEO and co-Founder of zPREDICTA. Julia’s vision for zPREDICTA is to to create a fully automated end-to-end workflow for drug development applying zPREDICTA’s patented of organ-specific 3D cell culture technology. Prior to founding zPREDICTA, Julia held a faculty appointment at the Department of Biological Sciences at Purdue University where her efforts focused on understanding the role of tumor microenvironment in cancer growth, spread, and response to therapy.